Skip to main content

Table 2 Multilevel modelling of changes in score from baseline to 12 month follow-up for remote cognitive behavioural therapy (RCBT) intervention versus treatment as usual (TAU)

From: Clinical and economic outcomes of remotely delivered cognitive behaviour therapy versus treatment as usual for repeat unscheduled care users with severe health anxiety: a multicentre randomised controlled trial

 

RCBT

TAU

Comparison

N

Mean change from baseline (95% CI)

N

Mean change from baseline (95% CI)

Difference (95% CI)

P-value

SHAI

 3 months

53

–6.08(–7.90 to –4.26)

48

–5.97(–7.97 to –3.97)

–0.11(–2.82 to 2.60)

0.936

 6 months

56

–9.48(–11.20 to –7.75)

56

–6.67(–8.30 to –5.04)

–2.81(–5.11 to –0.50)

0.017

 9 months

46

–9.58(–11.33 to –7.84)

50

–6.78(–8.43 to –5.12)

–2.81(–5.11 to –0.50)

0.017

 12 months

47

–10.60(–12.31 to –8.89)

47

–7.79(–9.43 to –6.16)

–2.81(–5.11 to –0.50)

0.017

GAD 7

 3 months

52

–3.69(–5.09 to –2.28)

48

–4.79(–6.17 to –3.41)

1.10(–0.84 to 3.05)

0.265

 6 months

53

–6.22(–7.62 to –4.82)

55

–3.83(–5.21 to –2.44)

–2.39(–4.40 to –0.39)

0.020

 9 months

43

–5.37(–7.05 to –3.69)

48

–4.48(–5.97 to –2.99)

–0.89(–3.00 to 1.23)

0.408

 12 months

45

–6.68(–8.14 to –5.21)

46

–3.92(–5.40 to –2.45)

–2.75(–4.82 to –0.68)

0.009

PHQ9

 3 months

52

–3.24(–4.69 to –1.80)

47

–3.01(–4.38 to –1.64)

–0.23(–2.15 to 1.68)

0.812

 6 months

53

–4.67(–6.02 to –3.33)

55

–3.11(–4.46 to –1.76)

1.56(–3.45 to 0.33)

0.105

 9 months

43

–4.41(–6.06 to –2.76)

48

–3.24(–4.78 to –1.69)

–1.17(–3.18 to 0.83)

0.250

 12 months

45

–5.05(–6.37 to –3.72

45

–2.69(–4.06 to –1.31)

–2.36(–4.22 to –0.50)

0.013

PHQ15

 3 months

52

–0.35(–1.58 to 0.88)

48

–1.68(–3.16 to –0.19)

1.33(–0.52 to 3.17)

0.157

 6 months

54

–2.95(–4.11 to –1.78)

55

–1.62(–2.90 to –0.34)

–1.33(–3.09 to 0.42)

0.137

 9 months

45

–2.62(–4.19 to –1.04)

49

–2.20(–3.47 to –0.92)

–0.42(–2.38 to 1.53)

0.669

 12 months

46

–3.33(–4.62 to –2.04)

47

–1.77(–2.99 to –0.55)

–1.57(–3.37 to 0.24)

0.089

EQ5D–5L (VAS)

 3 months

52

8.74 (3.70 to 13.79)

47

2.80(–2.35 to 7.96)

5.94(–1.22 to 13.11)

0.103

 6 months

54

13.66 (8.97 to 18.34)

55

11.10 (6.32 to 15.89)

2.56(–4.03 to 9.14)

0.446

 9 months

45

10.24 (5.28 to 15.21)

49

2.92 (–2.06 to 7.90)

7.33(–0.02 to 14.67)

0.051

 12 months

46

13.80 (8.90 to 18.71)

47

4.25 (–0.87 to 9.37)

9.56 (2.73 to 16.39)

0.006

WSAS

 3 months

51

–4.45(–6.63 to –2.27)

48

–3.36(–5.61 to –1.10)

–1.10(–4.07 to 1.87)

0.468

 6 months

53

–7.52(–9.85 to –5.19)

55

–4.89(–7.03 to –2.75)

–2.63(–5.72 to 0.45)

0.094

 9 months

44

–7.31(–9.81 to –4.81)

56

–5.77(–8.15 to –3.39)

–1.54(–4.99 to 1.90)

0.377

 12 months

45

–7.89(–10.22 to –5.56)

56

–5.40(–7.79 to –3.01)

–2.49(–5.73 to 0.75)

0.131

 

RCBT

TAU

Unadjusted difference in change

 

N

Mean (SD)

n

Mean (SD)

Mean (95% CI) (P-value)

QALYsa at 12 months

31

0.66 (0.22)

25

0.59 (0.31)

0.07 (0.07 to 0.21) (0.332)

  1. aQALYs at 12 months is based on the complete dataset over the 12-month follow-ups